Abstract: Provided herein are methods of treating at least one symptom of ALS in a subject, the method comprising administering to a subject who has received an inhibitor of a transporter a first dosage of a composition comprising TURSO and sodium phenylbutyrate; determining or having determined a first level of TURSO, sodium phenylbutyrate, or a metabolite thereof, in a first biological sample from the subject; and administering to the subject a second dosage of the composition.

Abstract: Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound.

Abstract: Provided herein are methods for treating at least one symptom of ALS in a subject who has received a first dosage of BSEP inhibitor, the method including administering to the subject a composition comprising a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound, monitoring the subject for response to the B SEP inhibitor, and administering a second dosage of the BSEP inhibitor, wherein the second dosage is less than the first dosage.

Abstract: Provided herein are methods and compositions for treating a neurodegenerative disease (e.g., ALS). The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound.

Abstract: Provided herein are methods for treating at least one symptom of ALS in a subject who has received a first dosage of BSEP inhibitor, the method including administering to the subject a composition comprising a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound, monitoring the subject for response to the BSEP inhibitor, and administering a second dosage of the BSEP inhibitor, wherein the second dosage is less than the first dosage.

Abstract: Embodiments of a device facilitate controlled positioning and manipulation of an individual's relative head, neck and jaw positions to facilitate stable airway management. In various embodiments, the device includes a base to which support arms are movably attached. A thrust arm is movably attached to each support arm and a jaw disc is attached to each thrust arm and adapted for rotation in accommodating various shapes and sizes of patient jaws.

Abstract: Provided herein are methods for treating at least one symptom of ALS in a subject who has received a first dosage of a substrate of a CYP or a transporter, the method including administering to the subject a composition comprising a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound, monitoring the subject for response to the substrate, and administering a second dosage of the substrate, wherein the second dosage is less than the first dosage.

Abstract: The present disclosure relates to compositions including a phenylbutyrate compound and a bile acid, and methods of processing such compositions.

Abstract: Embodiments of a device facilitate controlled positioning and manipulation of an individual's relative head, neck and jaw positions to facilitate stable airway management. In various embodiments, the device includes a base to which support arms are movably attached. A thrust arm is movably attached to each support arm and a jaw disc is attached to each thrust arm and adapted for rotation in accommodating various shapes and sizes of patient jaws.

Abstract: The present disclosure relates to compositions including a phenylbutyrate compound and a bile acid, and methods of processing such compositions.

Abstract: The present disclosure relates to compositions including a phenylbutyrate compound and a bile acid, and methods of processing such compositions.

Abstract: Embodiments of a device facilitate controlled positioning and manipulation of an individual's relative head, neck and jaw positions to facilitate stable airway management. In various embodiments, the device includes a base to which support arms are movably attached. A thrust arm is movably attached to each support arm and a jaw disc is attached to each thrust arm and adapted for rotation in accommodating various shapes and sizes of patient jaws.

Abstract: This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metabolite-mediated oxidative damage in a cell, regulating redox homeostasis in a cell, or reducing mitochondrial dysfunction in a cell. The invention further relates to the administration of the bile acid tauroursodeoxycholic acid (TUDCA) in combination with phenylbutyric Acid (PBA) to improve cell viability, and treat at least one symptom associated with, prevent the time of onset of, or slow the development of a disease related to oxidative stress.

Abstract: Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound.

Abstract: Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound.

Abstract: Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound.

Abstract: Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound.

Abstract: Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound.

Abstract: Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound.

Abstract: Provided herein are methods and compositions for treating at least one symptom of ALS, slowing ALS disease progression, or reducing the deterioration of one or more bodily functions affected by ALS in a subject. The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound.